Summary.We investigated the role of the drug resistancerelated proteins LRP, MRP and Pgp and the apoptotic suppressor, bcl-2, in relation to other clinical characteristics, with respect to response and survival in 91 patients with newly diagnosed AML, treated with standard chemotherapy. Multivariate analysis showed that poor response to chemotherapy was associated with increasing age (P ¼ 0·0004), LRP expression (P ¼ 0·0001) and Pgp function (P ¼ 0·015). The significant predictors of both leukaemia-free survival (LFS) and overall survival (OS) were LRP (LFS, P ¼ 0·01; OS, P ¼ 0·0001), Pgp function (LFS, P ¼ 0·0001; OS, P ¼ 0·0003) and cytogenetic abnormalities (LFS, P ¼ 0·0001; OS, P ¼ 0·0005). Patients with the lowest expression of LRP and Pgp function and favourable karyotype (group I) had an LFS of 30·2 months compared to 8·5 months in the group with the highest expression of LRP and Pgp and poor prognosis karyotype (group III, P ¼ 0·002). OS decreased from 75·4 months in group I to 7·9 months in group III patients (P < 0·0001). Neither MRP nor bcl-2 were significantly associated with chemotherapy response and survival. Correlations were found between increasing expression of LRP and older age (P ¼ 0·05) and an unfavourable karyotype (P ¼ 0·005), but these variables were independent of each other in analysis of treatment response and patient survival. Our findings suggest that both LRP and Pgp are clinically relevant drug-resistance proteins and it may be necessary to modulate both LRP and Pgp functions in order to reverse the multidrug resistance phenotype in AML.

Summary. The in vitro intracellular daunorubicin accumulation (IDA) of blast cells from 69 patients with newly diagnosed acute myeloid leukaemia (AML) was correlated with the expression and functional activity of the multidrug resistance (MDR) proteins, P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP) and lung-resistance protein (LRP). An inverse and signi®cant association was found between IDA and Pgp-related ef¯ux activity (r À0´31, P 0´01) and also MRP (r À0´25, P 0´04) but not with LRP (r À0´13, P 0´28). Coexpression of the MDR proteins had an additive effect in further lowering of IDA levels, suggesting that the clinical MDR phenotype is dependent on the sum of multiple MDR factors available to the leukaemic cell. Thus, the median IDA of leukaemic cells without any MDR proteins was signi®cantly higher than that of blasts carrying two MDR proteins (0´466 vs. 0´296, P 0´046). Seven patients with no expression of Pgp, MRP and LRP still had low IDA levels, suggesting the presence of ef¯ux MDR mechanisms other than those studied. The relation of IDA to clinical parameters known to be associated with poor prognosis, such as age, secondary AML, karyotype, peripheral blood blast and CD34 counts, was also studied, but no signi®cance was found on multifactorial analysis. There was a non-signi®cant trend for earlier relapse in patients with low IDA levels (leukaemia-free survival of 16´3 months compared with 21´1 months in patients with high IDA levels). Our data suggest that, while the IDA assay is a quick and relatively easy test for the combined ef¯ux MDR phenotype, it is unable to detect other MDR mechanisms, such as LRP, which may be important to the clinical outcome of patients with AML.

No abstract